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Abstrak 
Pandemi COVID-19 menyebabkan morbiditas dan kematian yang di seluruh dunia. Pasien dengan usia yang 
lebih tua, laki-laki dan memiliki komorbiditas sebelumnya seperti penyakit ginjal kronis atau chronic kidney disease 
(CKD) dilaporkan lebih mudah terinfeksi SARS CoV-2 dan berisiko lebih tinggi untuk menjadi kasus berat atau bahkan 
kematian. Dilaporkan seorang laki-laki  usia 24 tahun dirawat di rumah sakit dengan keluhan sesak napas, batuk, 
demam dan pucat. Riwayat kontak dengan kasus terkonfirmasi COVID-19 tidak jelas. Pasien seorang petugas 
keamanan. Riwayat hipertensi ada. Hasil laboratorium menunjukkan hemoglobin 7 g/dl, ureum 261 mg/dl, dan 
kreatinin 22,9 mg/dl. Pada hari kedua rawatan, sesak napas meningkat, penurunan kesadaran dan epistaksis. Hasil 
swab nasofaring didapatkan hasil positif COVID-19 dan diberikan Oseltamivir 75 mg. Pasien dillakukan hemodialisis di 
ruang isolasi. Setelah hemodialisis, kondisi pasien membaik dengan sesak napas berkurang dan peningkatan 
kesadaran. Pasien keluar dari ruang isolasi dan dipulangkan dalam kondisi baik. Terapi antivirus pada pasien CKD 
dengan infeksi COVID-19 membutuhkan penyesuaian dosis. Hemodialisis segera diperlukan pada pasien dengan 
CKD dan infeksi COVID-19  untuk memperbaiki kondisi pasien. Manajemen yang cepat untuk pasien dengan CKD dan 
COVID-19 akan mengurangi risiko kematian. 
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Abstract 
The COVID-19 pandemic has caused substantial morbidity and mortality worldwide. Older patients, male gender 
and those with preexisting comorbidities such as chronic kidney disease are reported to be more likely infected with 
SARS CoV-2 and are at higher risk of severe illness or death. It has been reported a 24 years old male was admitted 
to the hospital with shortness of breath, coughing, fever and paleness. The history of contact with confirmed COVID-19 
cases was unclear. The patient works as a security officer. A history of hypertension is present. Laboratory results 
showed hemoglobin 7 g/dl, ureum 261 mg/dl, and creatinine 22,9 mg/dl. On the second day of admission, the patient 
experience increased shortness of breath, decreased consciousness and epistaxis. From the result of the 
nasopharyngeal swab, the patient tested positive for COVID-19 and was given Oseltamivir 75mg. The patient is 
prepared for hemodialysis, which was performed in the isolation room. After hemodialysis, the patient's condition 
improved with decreased shortness of breath and increased of consciousness. The patient comes out from the 
isolation room and discharges home in good condition. Antiviral therapy in CKD patients with Covid-19 infection 
requires dose adjustment. Immediate hemodialysis is required in patients with CKD and coexisting COVID-19 infection 
to improve the patient's condition. Prompt management for patients with CKD and COVID-19 will reduce the risk of 
mortality. 
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INTRODUCTION 
In year 2019 in Wuhan, an unknown cause of 
pneumonia case was reported and it was finally known 
as a disease caused by a new virus. It rapidly spread, 
which resulted an epidemic throughout China, with the 
sporadic cases reported globally, which caused a 
global health emergency.1 In February 2020, the World 
Health Organization (WHO) named the new virus 
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Disease 2019 (COVID-19).2 The COVID-19 pandemic 
has caused substantial morbidity and mortality 
worldwide in an effort to contain the COVID-19 
pandemic, an understanding of the epidemiology of 
the disease is needed. Clinicians need to know which 
individuals are more at risk of SARS-CoV-2 infection 
as well as the risk of morbidity and mortality.3,4 
Although patients of all ages are susceptible to the 
disease, individuals developing critical illness were 
older and had a greater number of comorbid 
conditions with high mortality rates and poor 
outcomes.5 
Kidney failure is a severe medical condition with 
a high prevalence of comorbid conditions, including 
diabetes and heart disease, which disproportionately 
affect older adults.6 Patients with chronic kidney 
disease (CKD) are expected to be at higher risk of 
severe disease since their rate of all-type of infections 
and the prevalence of cardiovascular disease are 
higher than in the general population.7 Marked 
alterations in the immune system have been reported 
in CKD patients, leading to an immunosuppressed 
state and frequent infection complications.8,9 
 
 
CASE   
We report a case of a 24 years old male admitted 
to the hospital with shortness of breath, coughing, 
fever and paleness. The history of contact with 
confirmed COVID-19 cases is unclear. The patient 
works as a security officer. A history of hypertension is 
present. Laboratory results showed hemoglobin 7 g/dl, 
ureum 261 mg/dl, and creatinine 22,9 mg/dl. On the 
second day of admission, the patient experience 
increased shortness of breath, decreased 
consciousness and epistaxis. From the result of the 
nasopharyngeal swab, the patient tested positive for 
COVID-19. 
The patient was diagnosed with CKD stage 5 
with uremic encephalopathy, uremic bleeding and 
confirmed COVID-19. The patient was given 
Oseltamivir 75 mg as antiviral therapy. The patient 
was prepared for hemodialysis, and hemodialysis was 
performed in the isolation room. After hemodialysis, 
the patient's condition improved with decreased 
shortness of breath and increased consciousness. The 
patient shifted out of the isolation room and was 
discharged home in good condition. 
 
 
Figure 1. Chest X-ray 
 
DISCUSSION 
A 24 years old male patient with CKD stage 5 
with uremic encephalopathy, uremic bleeding and 
confirmed COVID-19. The diagnosis of CKD stage V 
has been made from creatinine levels and eGFR 2 
ml/min/1,73m2. COVID-19 was confirmed from the 
result of the nasopharyngeal swab. 
For most patients, COVID-19 will affect mainly 
the upper and lower respiratory tract. The primary 
mode of infection is human-to-human transmission 
through close contact, which occurs via droplets from 
an infected individual through coughing or sneezing. 
Additionally, surfaces are thought to retain the virus for 
variable periods of time, depending on their nature.4,10 
Other organs might be affected by SARS-CoV-2, 
including the kidneys, ileum and heart, especially in 
the presence of viremia. Thus cultured renal proximal 
tubular epithelial cells and glomerular mesangial cells 
may represent another target for COVID-19.11 CKD 
causes marked alterations in the immune system, 
including persistent systemic inflammation and 
acquired immunosuppression. Multiple factors 
contribute to chronic inflammation in CKD, including 
patient-related factors, oxidative stress, and 
infections.8 
Once CKD patients become infected, they should 
be quarantined and, if on HD, dialyzed by fully 
protected personnel and separated from non-COVID-
19 patients, including transport to the HD facility, while 
in the facility and back home. Criteria for hospital 
admission are very variable, depending on whether 
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In patients with CKD, dose adjustments of 
antivirus drugs and side effects to the kidneys need to 
be considered. Some drugs required dosage 
adjustments, such as ribavirin, oseltamivir and 
chloroquine.8,14,15 In this particular case, the patient 
was given Oseltamivir 75mg once daily. Oseltamivir is 
a neuraminidase inhibitor, which reduces the virus 
replication in a dose-dependent manner, and prevents 
the impairment of the epithelial barrier function and 
cytotoxicity.16 Oseltamivir is an antivirus used for type 
A and B influenza therapy. This drug is secreted to the 
kidneys, therefore, requires dose adjustment in 
patients with kidney disorders.17,18 Thus, dosages and 
intake frequency have to be altered to reduce 
complications that could arise due to the poor renal 
performance of the patients.19 At the beginning, 
Oseltamivir was used as empirical therapy for the 
COVID-19 cases before the discovery of causatives 
therapy for SARS-COV-2.5,20 
 
CONCLUSION 
Prompt management for patients with CKD and 
COVID-19 will reduce the risk of mortality. 
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